Abstract:The commonly used host for industrial production of recombinant proteins Pichia pastoris, has been used in this work to produce the rabies virus glycoprotein (RABV-G). To allow a constitutive expression and the secretion of the expressed recombinant RABV-G, the PichiaPink™ commercialized expression vectors were modified to contain the constitutive GAP promoter and the α secretion signal sequences. Recombinant PichiaPink™ strains co-expressing the RABV-G and the protein chaperone PDI, have been then generated and screened for the best producer clone. The influence of seven carbon sources on the expression of the RABV-G, has been studied under different culture conditions in shake flask culture. An incubation temperature of 30°C under an agitation rate of 250 rpm in a filling volume of 10:1 flask/culture volume ratio were the optimal conditions for the RABV-G production in shake flask for all screened carbon sources. A bioreactor Fed batch culture has been then carried using glycerol and glucose as they were good carbon sources for cell growth and RABV-G production in shake flask scale. Cells were grown on glycerol during the batch phase then fed with glycerol or glucose defined solutions, a final RABV-G concentration of 2.7 µg/l was obtained with a specific product yield (YP/X) of 0.032 and 0.06 µg/g(DCW) respectively. The use of semi-defined feeding solution enhanced the production and the YP/X to 12.9 µg/l and 0.135 µg/g(DCW) respectively. However, the high cell density favored by these carbon sources resulted in oxygen limitation which influenced the glycosylation pattern of the secreted RABV-G. Alternatively, the use of sucrose as substrate for RABV-G production in large scale culture, resulted in less biomass production and a YP/X of 0.310 µg/g(DCW) was obtained. A cation exchange chromatography was then used for RABV-G purification as one step method. The purified protein was correctly folded and glycosylated and able to adopt trimeric conformation. The knowledges gained through this work offer a valuable insight into the bioprocess design of RABV-G production in Pichia pastoris to obtain a correctly folded protein which can be used during an immunization proposal for subunit Rabies vaccine development.

Application of a caprylate/chromatography purification process for production of a high potency rabies immune globulin from pooled human plasma

Rabbit Anti-Rabies Immunoglobulins Production and Evaluation

A cocktail of human monoclonal antibodies broadly neutralizes North American rabies virus variants as a promising candidate for rabies post-exposure prophylaxis

Expression, purification and characterization of a human single-chain Fv antibody fragment fused with the Fc of an IgG1 targeting a rabies antigen in Pichia pastoris.

Development of Human Monoclonal Antibodies With Broad Reactivity for Rabies Postexposure Prophylaxis

Development of broad-spectrum human monoclonal antibodies for rabies post-exposure prophylaxis

Purification and On-Column Refolding of a Single-Chain Antibody Fragment Against Rabies Virus Glycoprotein Expressed in Escherichia Coli.

Preparation and diagnostic use of a novel recombinant single-chain antibody against rabies virus glycoprotein

Rapid fluorescent focus inhibition test optimization and validation: Improved detection of neutralizing antibodies to rabies virus

A Novel Variable Antibody Fragment Dimerized by Leucine Zippers with Enhanced Neutralizing Potency Against Rabies Virus G Protein Compared to Its Corresponding Single-Chain Variable Antibody Fragment

Characterization of a human–mouse chimeric monoclonal antibody targeting rabies virus glycoprotein

Efficacy of ormutivimab, a novel recombinant human anti-rabies monoclonal antibody, in post-exposure prophylaxis animal models

Rabies Prophylactic and Treatment Options: An In Vitro Study of siRNA- and Aptamer-Based Therapeutics

Production, purification, and characterization of recombinant rabies virus glycoprotein expressed in PichiaPink™ yeast

Characterization Of A Human Antibody Fragment Fab And Its Calcium Phosphate Nanoparticles That Inhibit Rabies Virus Infection With Vaccine

Development of a novel bispecific antibody GR1801 for rabies

Analysis of the antigenic and immunogenic properties of the native rabies virus glycoprotein purified by Lens culinaris lectin affinity chromatography

A Novel Disulfide-Stabilized Single-Chain Variable Antibody Fragment Against Rabies Virus G Protein with Enhanced in Vivo Neutralizing Potency

Generation and Characterization of the Human Neutralizing Antibody Fragment Fab091 Against Rabies Virus

Post-Marketing Surveillance of the World's First Novel Cocktail of Rabies Monoclonal Antibodies: TwinRab™ in Real \-World Setting

Immunogenicity and Antigenicity of the Ectodomain of Rabies Virus Glycoprotein Stably Expressed in HEK293T Cells